BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review)

  • Authors:
    • Wei He
    • Huixian Hu
  • View Affiliations

  • Published online on: May 8, 2018     https://doi.org/10.3892/or.2018.6422
  • Pages: 3-15
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Heat shock proteins (HSPs) are molecular chaperones that are consistently increased to help cells survive under conditions of stress. As a member of the Hsps, Hsp90 is involved in protein post‑translational maturation and disposition. This protein is ubiquitously expressed in normal cells. However, in cancer cells and particularly in hematological malignancies, Hsp90 is unexpectedly abundant to maintain levels of proteins vital for cancer pathology. Hsp90 inhibitors can target the ATP domain of Hsp90 and prohibit its exchange of ADP for ATP, leading to the degradation of client proteins and disruption of signaling cascades. Concomitantly, Hsp90 inhibitors induce tumor cell apoptosis, promote cell cycle arrest and abrogate microenvironment‑derived cytoprotection. Geldanamycin, a benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus, and its derivative, 17‑AAG, were first developed as Hsp90 inhibitors and exhibited effective anticancer potency. Whereas, severe side effects and low solubility restricted their application at the clinical level, BIIB021, a novel and fully synthetic inhibitor of Hsp90, is water soluble and well‑tolerated. Beyond degrading oncogenic protein, BIIB021 can overcome multidrug resistance and potentiate the effects of other therapeutics. phase I/II trials have been conducted to evaluate the dosing schedules and activity of this agent. The present review focuses on the antitumor profile of BIIB021. Furthermore, given the promising efficacy of BIIB021 in leukemia and lymphoma, this review also discusses current research concerning the treatment of hematologic malignancies by targeting Hsp90.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 40 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
He W and Hu H: BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). Oncol Rep 40: 3-15, 2018.
APA
He, W., & Hu, H. (2018). BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). Oncology Reports, 40, 3-15. https://doi.org/10.3892/or.2018.6422
MLA
He, W., Hu, H."BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review)". Oncology Reports 40.1 (2018): 3-15.
Chicago
He, W., Hu, H."BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review)". Oncology Reports 40, no. 1 (2018): 3-15. https://doi.org/10.3892/or.2018.6422